MET and non-small cell lung carcinoma: Although EGFR-sensitive mutation is very common in the Asian population, and MET amplification as a de novo driver alteration occurring in untreated NSCLC patients is approximately 1%–5% (7, 8), the co-harboring EGFR Ex19del mutation and MET de novo amplification is really rare (18, 19).